Bioresorbable vascular scaffold: promises and the fallen child-as-king?
作者信息
Cook Stephane, Meier Pascal
机构信息
Department of Cardiology , Hospital & University Fribourg , Fribourg , Switzerland.
Department of Cardiology, University Hospital Geneva, Geneva, Switzerland; Institute of Cardiovascular Science, University College London UCL, London, UK.
出版信息
Open Heart. 2016 Oct 5;3(2):e000527. doi: 10.1136/openhrt-2016-000527. eCollection 2016.
Abstract
摘要
相似文献
1
Bioresorbable vascular scaffold: promises and the fallen child-as-king?
Open Heart. 2016 Oct 5;3(2):e000527. doi: 10.1136/openhrt-2016-000527. eCollection 2016.
2
Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds.
Int J Cardiol. 2016 Mar 1;206:58-60. doi: 10.1016/j.ijcard.2016.01.091. Epub 2016 Jan 7.
3
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
4
Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017.
5
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022.
6
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.
7
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.
8
Initial experience in the clinical use of everolimus-eluting bioresorbable vascular scaffold (BVS) in a single institution.
Int J Cardiol. 2013 Sep 30;168(2):1536-7. doi: 10.1016/j.ijcard.2012.12.037. Epub 2013 Jan 3.
9
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30.
10
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
JACC Cardiovasc Interv. 2015 Jul;8(8):1053-1063. doi: 10.1016/j.jcin.2015.06.001.
引用本文的文献
1
Bioresorbable Vascular Scaffolds in Interventional Neuroradiology.
Clin Neuroradiol. 2018 Dec;28(4):585-592. doi: 10.1007/s00062-017-0609-5. Epub 2017 Jul 26.
本文引用的文献
1
Use of bioresorbable vascular scaffold: a meta-analysis of patients with coronary artery disease.
Open Heart. 2016 Aug 25;3(2):e000462. doi: 10.1136/openhrt-2016-000462. eCollection 2016.
2
Bioresorbable vascular scaffolds-time to vanish?
J Thorac Dis. 2016 Jun;8(6):E431-6. doi: 10.21037/jtd.2016.04.50.
3
Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1203-1212. doi: 10.1016/j.jcin.2016.03.038. Epub 2016 Jun 1.
4
Mechanisms of Late and Very Late Bioresorbable Vascular Scaffold Thrombosis: Is it Only About Flow?
J Am Coll Cardiol. 2016 Mar 15;67(10):1259-1260. doi: 10.1016/j.jacc.2015.11.062.
5
Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors.
J Am Coll Cardiol. 2016 Mar 1;67(8):921-931. doi: 10.1016/j.jacc.2015.12.019.
6
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
Lancet. 2016 Mar 26;387(10025):1277-89. doi: 10.1016/S0140-6736(15)01039-9. Epub 2016 Jan 27.
7
Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis.
JACC Cardiovasc Interv. 2016 Jan 11;9(1):12-24. doi: 10.1016/j.jcin.2015.09.024.
8
Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
Lancet. 2016 Feb 6;387(10018):537-544. doi: 10.1016/S0140-6736(15)00979-4. Epub 2015 Nov 17.
9
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
N Engl J Med. 2015 Nov 12;373(20):1905-15. doi: 10.1056/NEJMoa1509038. Epub 2015 Oct 12.
10
Optical Coherence Tomography Findings in Bioresorbable Vascular Scaffolds Thrombosis.
Circ Cardiovasc Interv. 2015 Oct;8(10):e002518. doi: 10.1161/CIRCINTERVENTIONS.114.002518.
Zotero 插件